Literature DB >> 6202984

The ergoloid mesylate dihydroergotoxine: radioimmunoassay measurements on plasma and blood-pressure-lowering activity.

B G Woodcock, W D Habedank, W Loh, N Rietbrock.   

Abstract

Dihydroergotoxine plasma concentrations determined using a newly developed radioimmunoassay method and corresponding blood-pressure-lowering effects have been measured in normotensive subjects after intravenous injection (0.6 mg) and administration of an oral solution (4.5 mg). Plasma concentrations in the range 0.2-1 ng/ml dihydroergotoxine produced clinically significant reductions of up to 15% in systolic and diastolic standing and supine blood pressures, while no significant changes occurred in pulse rate.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202984

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

1.  Absorption kinetics of dihydroergotoxine following oral administration to man.

Authors:  B G Woodcock; N Rietbrock; W Loh; W D Habedank
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

2.  The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects.

Authors:  P Dominiak; J Grevel; E Abisch; H Grobecker; H J Dennler; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.